Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Astrana Health Q1 2026 Earnings Call - AI-Driven Operating Leverage Accelerates Deleveraging
Astrana Health delivered a strong first quarter, with revenue of $965.1 million, up 56% year-over-year, and adjusted EBITDA of $66.3 million, up 82% year-over-year. The company's AI-enabled platform i...
- Revenue of $965.1 million, up 56% year-over-year, driven by full quarter contribution from Prospect and new full risk contracts.
- Adjusted EBITDA of $66.3 million, up 82% year-over-year, reflecting strong operating leverage and disciplined growth.
- Non-GAAP adjusted EPS of $0.74, up 76% year-over-year, with free cash flow of $64.1 million.
- +7 more takeaways
WillScot Mobile Mini Q1 2026 Earnings Call - Leasing Revenue Inflection Accelerated to Second Half 2026
WillScot Mobile Mini kicked off 2026 with a solid first quarter, delivering $549 million in revenue and $211 million in adjusted EBITDA, both exceeding expectations. The company raised its full-year g...
- Total revenue came in at $549 million, modestly lower year-over-year due to local market softness, but ahead of internal expectations.
- Adjusted EBITDA reached $211 million, beating the pre-call outlook despite margin compression from higher variable costs and delivery mix.
- Leasing and services revenue grew modestly by $2 million year-over-year, signaling the first signs of top-line stabilization.
- +11 more takeaways
Coinbase Q1 2026 Earnings Call - Market Share Hits Record as AI and Stablecoins Drive Shift to On-Chain Finance
Coinbase reported Q1 2026 revenue of $1.4 billion with a $394 million net loss, driven by a 21% sequential drop in crypto trading volumes. Despite the macro headwinds, the company reached an all-time ...
- Total revenue fell 21% sequentially to $1.4 billion, reflecting a 20%+ drop in crypto market cap and trading volumes, yet the company delivered within or above its guidance ranges.
- Crypto trading market share reached an all-time high, with the platform gaining share in both spot and derivatives despite a softer macro environment.
- Native unit inflows have continued for 12 consecutive quarters, demonstrating that trust and brand dominance are driving asset accumulation even during price declines.
- +7 more takeaways
Puma Biotechnology Q1 2026 Earnings Call - Alisertib Shows Biomarker-Driven Activity in Lung and Breast Cancer as NERLYNX Sales Stabilize
Puma Biotechnology reported Q1 2026 total revenue of $44.8 million, driven by $42 million in NERLYNX net product sales and $2.8 million in royalties. While product revenue declined sequentially due to...
- Total revenue for Q1 2026 was $44.8 million, comprising $42 million in NERLYNX net product sales and $2.8 million in royalties.
- NERLYNX net product revenue of $42 million declined sequentially from $59.9 million in Q4 2025, primarily due to a $7.9 million inventory drawdown at specialty pharmacies and distributors.
- New prescriptions for NERLYNX increased approximately 25% quarter-over-quarter, while total prescriptions declined only 4%, indicating stabilizing demand.
- +7 more takeaways
IREN Q3 FY 2026 Earnings Call - NVIDIA Partnership and Global Expansion
IREN reported Q3 FY 2026 results highlighting a strategic pivot from Bitcoin mining to AI Cloud infrastructure, underscored by a major partnership with NVIDIA. The company secured a $3.4 billion five-...
- IREN secured a $3.4 billion five-year AI Cloud contract with NVIDIA, marking the first step in a broader strategic partnership.
- NVIDIA committed a $2.1 billion investment that vests as IREN deploys GPU infrastructure, fully vesting upon deployment of 600,000 GPUs.
- IREN increased secured power capacity to 5 gigawatts globally, with expansions in North America, Europe, and APAC.
- +7 more takeaways
BRC Group Holdings Q1 2026 Earnings Call - Debt Reduction and Investment Gains Drive Profitability
BRC Group Holdings reported a strong first quarter 2026, driven by significant investment gains and a deliberate focus on balance sheet optimization. Net income surged to $211.3 million, a stark rever...
- Net income available to common shareholders reached $211.3 million, a dramatic turnaround from a $12 million net loss in Q1 2025, driven by $161 million in higher trading gains.
- Adjusted EBITDA rose to $262.2 million from a $45 million loss in the prior year, with operating adjusted EBITDA up nearly 40% sequentially to $34.6 million.
- Total debt was reduced by $129 million during the quarter, with net debt standing at $372 million, down approximately $255 million from year-end.
- +7 more takeaways
Corpay Q1 2026 Earnings Call - Corporate Payments Surge Drives Guideline Hike
Corpay delivered a blowout first quarter, with revenue up 25% and cash EPS rising 29%, driven by a 16% surge in corporate payments and strong momentum across its cross-border and payables segments. Th...
- Revenue surged 25% to $1.26 billion, with cash EPS up 29% to $5.80, marking a fourth consecutive quarter of 11% organic growth.
- Full-year 2026 revenue guidance raised to $5.29 billion and cash EPS guidance increased to $26.70, reflecting a $50 million Q1 beat and stronger-than-expected rest-of-year performance.
- Corporate payments grew 16% organically (18% ex-float), now representing 40% of total revenue, driven by cross-border and payables momentum.
- +7 more takeaways
Afya Q1 2026 Earnings Call - Higher Tickets and Ecosystem Investments Drive Growth Despite Margin Compression
Afya reported a solid first quarter in 2026, with revenue up 8% year-over-year to BRL 1.013 billion and adjusted EBITDA reaching BRL 511 million. The growth was primarily driven by a 5% increase in me...
- Revenue grew 8% year-over-year to BRL 1.013 billion, driven by a 5% increase in medical school net average ticket prices and growth in non-medical health programs.
- Adjusted EBITDA reached BRL 511 million, up 4% year-over-year, but margins compressed by 200 basis points to 50.5% due to higher sales, marketing, and payroll expenses in new initiatives.
- Free cash flow increased 3% to BRL 376 million, with a robust cash conversion rate of 92.5% and a cash position of BRL 1.3 billion at quarter-end.
- +7 more takeaways
Rocket Lab Q1 2026 Earnings Call - Record $200M Revenue and Aggressive Neutron Progress Signal a Structural Shift in Space
Rocket Lab delivered its strongest first quarter in company history, with revenue surging 63.5% year-over-year to a record $200.3 million and backlog jumping 108% to $2.2 billion. The results undersco...
- Revenue hit a record $200.3 million, up 63.5% year-over-year and beating the high end of guidance, driven by a 57% surge in Space Systems and robust launch demand.
- Backlog jumped 108% year-over-year to $2.2 billion, with launch services accounting for 41.5% and space systems making up the remaining 58.5% as the company converted a robust pipeline into signed contracts.
- Neutron secured its largest contract in company history, a multi-launch agreement for five dedicated Neutron flights and three Electron launches through 2029, validating customer confidence ahead of the vehicle's first flight.
- +7 more takeaways
Microchip Technology Q4 FY2026 Earnings Call - Data Center Momentum and Inventory Correction Drive Strong Q4 Beat
Microchip Technology delivered a robust Q4 FY2026 performance, with net sales of $1.311 billion beating the high end of guidance and marking a 35.1% year-over-year increase. The company’s nine-point r...
- Q4 FY2026 net sales reached $1.311 billion, up 10.6% sequentially and 35.1% year-over-year, beating the high end of guidance.
- Non-GAAP gross margin improved to 61.6%, driven by reduced underutilization charges and capacity optimization, with a long-term target of 65%.
- Inventory levels decreased from 266 days in December 2024 to 185 days in March 2026, with distribution channels restocking as sell-through increases.
- +7 more takeaways